{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:35:40Z","timestamp":1790645740569,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/eye.2014.180","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T09:39:25Z","timestamp":1406885965000},"page":"1218-1222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration\u2014the role of oral acetazolamide in protecting glaucoma patients"],"prefix":"10.1038","volume":"28","author":[{"given":"C D","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Allgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R P","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"issue":"14","key":"BFeye2014180_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419\u20131431.","journal-title":"N Engl J Med"},{"issue":"14","key":"BFeye2014180_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432\u20131444.","journal-title":"N Engl J Med"},{"issue":"1","key":"BFeye2014180_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/eye.2012.225","volume":"27","author":"AH Ross","year":"2013","unstructured":"Ross AH, Donachie PH, Sallam A, Stratton IM, Mohamed Q, Scanlon PH et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond) 2013; 27 (1): 56\u201364.","journal-title":"Eye (Lond)"},{"issue":"11","key":"BFeye2014180_CR4","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP study group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120 (11): 2292\u20132299.","journal-title":"Ophthalmology"},{"issue":"6","key":"BFeye2014180_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ . Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am JOphthalmol 2008; 146 (6): 930\u20134 e1.","journal-title":"Am JOphthalmol"},{"issue":"8","key":"BFeye2014180_CR6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/IAE.0b013e3180592ba6","volume":"27","author":"IA Falkenstein","year":"2007","unstructured":"Falkenstein IA, Cheng L, Freeman WR . Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 2007; 27 (8): 1044\u20131047.","journal-title":"Retina"},{"issue":"6","key":"BFeye2014180_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3129\/i07-172","volume":"42","author":"H Hollands","year":"2007","unstructured":"Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J . Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42 (6): 807\u2013811.","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"BFeye2014180_CR8","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajo.2007.01.052","volume":"143","author":"RE Frenkel","year":"2007","unstructured":"Frenkel RE, Mani L, Toler AR, Frenkel MP . Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2007; 143 (6): 1034\u20131035.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"BFeye2014180_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1001\/archophthalmol.2010.297","volume":"128","author":"MP Frenkel","year":"2010","unstructured":"Frenkel MP, Haji SA, Frenkel RE . Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 2010; 128 (12): 1523\u20131527.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"BFeye2014180_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119 (6): 1175\u20131183.","journal-title":"Ophthalmology"},{"issue":"1","key":"BFeye2014180_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/14740330903418422","volume":"9","author":"U Schmidt-Erfurth","year":"2010","unstructured":"Schmidt-Erfurth U . Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010; 9 (1): 149\u2013165.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"BFeye2014180_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1055\/s-0029-1245201","volume":"227","author":"PE Theoulakis","year":"2010","unstructured":"Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM . Effect of brimonidine\/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 2010; 227 (4): 280\u2013284.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"7","key":"BFeye2014180_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","volume":"85","author":"K Kotliar","year":"2007","unstructured":"Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I . Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85 (7): 777\u2013781.","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"BFeye2014180_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1167\/iovs.04-0162","volume":"46","author":"IG Pallikaris","year":"2005","unstructured":"Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK . Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci 2005; 46 (2): 409\u2013414.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2014180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2014180","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2014180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:22:22Z","timestamp":1684430542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2014180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,1]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["BFeye2014180"],"URL":"https:\/\/doi.org\/10.1038\/eye.2014.180","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,1]]},"assertion":[{"value":"24 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mr Richard P Gale and Mr Gavin Walters have worked as consultants for and received educational grants from Novartis Pharmaceuticals UK. Their institution has performed Novartis-sponsored clinical trials. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}